8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Apr 13, 2026·SEC
Material company update
Mar 17, 2026·SEC
ImageneBio Inc(IMA)Earnings, Financials & Key Ratios
IMA•NASDAQ
Price updated Jun 13, 2026
AboutClinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitisShow more
- Revenue$800K-77.1%
- EBITDA-$47M-33.7%
- Net Income-$45M-24.0%
- EPS (Diluted)-10.76-954.9%
- Gross Margin-29.13%-129.1%
- EBITDA Margin-5927.25%-484.8%
- Operating Margin-6056.38%-472.9%
- Net Margin-5668.63%-442.6%
- ROE-35.01%-41.5%
- ROIC-35.94%-0.1%
- Debt/Equity0.08+25.7%
IMA Key Insights
ImageneBio Inc (IMA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Share count reduced 89.9% through buybacks
- ✓Trading at only 0.2x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Sales declining 38.6% over 5 years
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when IMA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
IMA Price & Volume
ImageneBio Inc (IMA) stock price & volume — 10-year historical chart
Loading chart...
IMA Growth Metrics
ImageneBio Inc (IMA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-38.64%
3 Years-62.86%
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-8.07%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-439.22%
Return on Capital
10 Years-62.05%
5 Years-32.51%
3 Years-35.15%
Last Year-35.56%
IMA Peer Comparison
ImageneBio Inc (IMA) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SRZN | 174.9M | 23.39 | -0.72 | -67.37% | -45.71% | |||
 IMVT | 6.9B | 33.62 | -12.14 | -68.16% | 0.00 | |||
 KYMR | 7.04B | 86.21 | -23.36 | -16.72% | -6.12% | -25.02% | 0.05 | |
 ARQT | 3.05B | 24.38 | -187.54 | 91.34% | -0.57% | -1.41% | 0.03 | |
 PRTA | 431.91M | 8.25 | -1.82 | -92.84% | -260.92% | -49.88% | 0.05 | |
 ALNY | 37.74B | 282.85 | 121.39 | 65.19% | 13.46% | 98.29% | 1.62 | |
 RARE | 2.39B | 24.35 | -4.18 | 20.13% | -91.03% | -6.08% | ||
 FOLD | 4.55B | 14.49 | -164.85 | 20.05% | -4.27% | -12.02% | 1.76 |
Compare IMA vs Peers
ImageneBio Inc (IMA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
IMA Income Statement
ImageneBio Inc (IMA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 990K | 13.75M | 9.19M | 30.98M | 15.62M | 9.16M | 3.5M | 800K | 0 |
Revenue Growth % | - | 1289.19% | -33.15% | 237.01% | -49.59% | -41.35% | -61.79% | -77.14% | - |
Cost of Goods Sold | 38.99M | 24.94M | 44.85M | 47.11M | 64.32M | 1.02M | 0 | 1.03M | 780K |
COGS % of Revenue | 3937.98% | 181.33% | 487.79% | 152.03% | 411.84% | 11.14% | - | 129.12% | - |
Gross Profit | -38M▲ 0% | -11.19M▲ 70.6% | -35.65M▼ 218.8% | -16.12M▲ 54.8% | -48.7M▼ 202.1% | 8.14M▲ 116.7% | 3.5M▼ 57.0% | -233K▼ 106.7% | -780K▲ 0% |
Gross Margin % | -3837.98% | -81.33% | -387.79% | -52.03% | -311.84% | 88.86% | 100% | -29.13% | - |
Gross Profit Growth % | - | 70.56% | -218.76% | 54.78% | -202.07% | 116.71% | -57% | -106.66% | - |
Operating Expenses | 41.46M | 7.31M | 8.87M | 18.02M | 22.2M | 83.56M | 40.5M | 48.22M | 55.15M |
OpEx % of Revenue | 4188.08% | 53.13% | 96.43% | 58.14% | 142.15% | 912.19% | 1157.14% | 6027.25% | - |
Selling, General & Admin | 2.9M | 7.31M | 8.87M | 18.02M | 22.2M | 24.93M | 8.39M | 20.73M | 21.2M |
SG&A % of Revenue | 292.73% | 53.13% | 96.43% | 58.14% | 142.15% | 272.11% | 239.74% | 2590.75% | - |
Research & Development | 38.56M | 24.94M | 44.85M | 47.11M | 64.32M | 59.65M | 32.11M | 28.52M | 30.77M |
R&D % of Revenue | 3895.35% | 181.33% | 487.79% | 152.03% | 411.84% | 651.22% | 917.4% | 3565.63% | - |
Other Operating Expenses | 0 | -24.94M | -44.85M | -47.11M | -64.32M | -1.02M | 0 | -1.03M | 1.09M |
Operating Income | -40.89M▲ 0% | -18.49M▲ 54.8% | -44.52M▼ 140.7% | -34.14M▲ 23.3% | -70.9M▼ 107.7% | -75.42M▼ 6.4% | -37M▲ 50.9% | -48.45M▼ 30.9% | -55.93M▲ 0% |
Operating Margin % | -4130.71% | -134.46% | -484.22% | -110.18% | -453.99% | -823.33% | -1057.14% | -6056.38% | - |
Operating Income Growth % | - | 54.78% | -140.75% | 23.32% | -107.7% | -6.36% | 50.94% | -30.95% | - |
EBITDA | -40.47M | -18.25M | -44.22M | -33.59M | -70.15M | -74.4M | -35.47M | -47.42M | -53.44M |
EBITDA Margin % | -4088.08% | -132.69% | -480.95% | -108.42% | -449.18% | -812.19% | -1013.54% | -5927.25% | - |
EBITDA Growth % | - | 54.91% | -142.31% | 24.03% | -108.83% | -6.05% | 52.32% | -33.67% | -4.41% |
D&A (Non-Cash Add-back) | 422K | 243K | 300K | 544K | 751K | 1.02M | 1.53M | 1.03M | 648K |
EBIT | -40.87M | -18.49M | -44.52M | -34.14M | -70.9M | -75.42M | -37M | -48.45M | -53.78M |
Net Interest Income | 0 | 0 | 0 | 23K | 2.15M | 7.11M | 7.37M | 2.04M | 5.97M |
Interest Income | 0 | 0 | 0 | 23K | 2.15M | 7.11M | 7.37M | 2.04M | 6.06M |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 96K |
Other Income/Expense | 29K | 1.68M | 263K | 23K | 2.14M | 7.09M | 445K | 2.75M | 10.53M |
Pretax Income | -40.87M▲ 0% | -16.82M▲ 58.8% | -44.26M▼ 163.2% | -34.12M▲ 22.9% | -68.77M▼ 101.6% | -68.33M▲ 0.6% | -36.55M▲ 46.5% | -45.7M▼ 25.0% | -45.4M▲ 0% |
Pretax Margin % | -4127.78% | -122.28% | -481.36% | -110.1% | -440.29% | -745.94% | -1044.43% | -5712.38% | - |
Income Tax | 0 | 0 | 0 | 0 | 0 | -162K | 13K | -350K | -325K |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0.24% | -0.04% | 0.77% | 0.72% |
Net Income | -40.87M▲ 0% | -16.82M▲ 58.8% | -44.26M▼ 163.2% | -34.12M▲ 22.9% | -68.77M▼ 101.6% | -68.17M▲ 0.9% | -36.57M▲ 46.4% | -45.35M▼ 24.0% | -45.07M▲ 0% |
Net Margin % | -4127.78% | -122.28% | -481.36% | -110.1% | -440.29% | -744.17% | -1044.8% | -5668.63% | - |
Net Income Growth % | - | 58.85% | -163.16% | 22.91% | -101.57% | 0.87% | 46.35% | -24.01% | -8.07% |
Net Income (Continuing) | -40.87M | -16.82M | -44.26M | -34.12M | -68.77M | -68.17M | -36.57M | -45.35M | -45.07M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -1.14▲ 0% | -0.47▲ 58.8% | -3.16▼ 572.3% | -0.95▲ 69.9% | -1.90▼ 100.0% | -1.63▲ 14.2% | -1.02▲ 37.4% | -10.76▼ 954.9% | -4.02▲ 0% |
EPS Growth % | - | 58.77% | -572.34% | 69.94% | -100% | 14.21% | 37.42% | -954.9% | -439.22% |
EPS (Basic) | -1.14 | -0.47 | -3.16 | -0.95 | -1.90 | -1.63 | -1.02 | -10.76 | - |
Diluted Shares Outstanding | 35.85M | 35.85M | 13.99M | 35.98M | 36.19M | 41.74M | 48.26M | 4.87M | 11.21M |
Basic Shares Outstanding | 35.85M | 35.85M | 13.99M | 35.98M | 36.19M | 41.74M | 48.26M | 4.87M | 11.21M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
IMA Balance Sheet
ImageneBio Inc (IMA) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 19.98M | 85.2M | 165.97M | 236.52M | 160.01M | 178.66M | 127.17M | 140.29M | 122.01M |
Cash & Short-Term Investments | 18.16M | 82.08M | 162.49M | 232.22M | 156.95M | 175.47M | 124.39M | 75.78M | 117.21M |
Cash Only | 18.16M | 82.08M | 162.49M | 232.22M | 59.92M | 119.89M | 39.39M | 34.97M | 76.05M |
Short-Term Investments | 0 | 0 | 0 | 0 | 97.03M | 55.57M | 84.99M | 40.82M | 41.16M |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.3M | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | 591.3 | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
Other Current Assets | 582K | 1.27M | 1.54M | 629K | 964K | 1.15M | 2.78M | 63.21M | 4.8M |
Total Non-Current Assets | 696K | 769K | 2.44M | 11.36M | 12.25M | 13.43M | 14.34M | 12.69M | 14.68M |
Property, Plant & Equipment | 696K | 769K | 1.56M | 8.98M | 8.46M | 8.02M | 4.23M | 0 | 616K |
Fixed Asset Turnover | 1.42x | 17.88x | 5.88x | 3.45x | 1.85x | 1.14x | 0.83x | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7.51M |
Other Non-Current Assets | 0 | 0 | 872K | 2.39M | 3.79M | 5.41M | 10.11M | 12.69M | 14.06M |
Total Assets | 20.68M▲ 0% | 85.97M▲ 315.8% | 168.4M▲ 95.9% | 247.88M▲ 47.2% | 172.26M▼ 30.5% | 192.09M▲ 11.5% | 141.51M▼ 26.3% | 152.98M▲ 8.1% | 136.68M▲ 0% |
Asset Turnover | 0.05x | 0.16x | 0.05x | 0.13x | 0.09x | 0.05x | 0.02x | 0.01x | 0.00x |
Asset Growth % | - | 315.82% | 95.88% | 47.19% | -30.51% | 11.51% | -26.33% | 8.1% | 0.66% |
Total Current Liabilities | 3.82M | 24.3M | 28.33M | 27.19M | 21.5M | 14.21M | 10.78M | 11.23M | 6.63M |
Accounts Payable | 2.27M | 935K | 2.12M | 2.38M | 2.09M | 2.07M | 897K | 1.44M | 568K |
Days Payables Outstanding | 21.22 | 13.68 | 17.27 | 18.47 | 11.88 | 739.3 | - | 508.46 | 538.14 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.31M |
Deferred Revenue (Current) | 126K | 20.68M | 20.62M | 17.1M | 9.16M | 0 | 0 | 0 | 0 |
Other Current Liabilities | 126K | 1.16M | 2.2M | 2.83M | 5.11M | 3.4M | 1.75M | 7.53M | 3.76M |
Current Ratio | 5.22x | 3.51x | 5.86x | 8.70x | 7.44x | 12.58x | 11.80x | 12.49x | 18.39x |
Quick Ratio | 5.22x | 3.51x | 5.86x | 8.70x | 7.44x | 12.58x | 11.80x | 12.49x | 18.39x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 62.69M | 123.14M | 241.12M | 12.81M | 3.79M | 8.13M | 4.8M | 8.6M | 6.72M |
Long-Term Debt | 62.58M | 0 | 0 | 0 | 0 | 0 | 0 | 7.02M | 5.73M |
Capital Lease Obligations | 0 | 0 | 0 | 5.13M | 3.79M | 7.18M | 3.74M | 713K | 3.95M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 78.87M | 205.98M | 0 | 0 | 950K | 1.06M | 870K | 881K |
Total Liabilities | 66.52M | 147.44M | 269.45M | 40M | 25.29M | 22.34M | 15.58M | 19.84M | 13.36M |
Total Debt | 62.58M | 0 | 186K | 6.99M | 5.69M | 10.74M | 7.52M | 9.99M | 8.15M |
Net Debt | 44.42M | -82.08M | -162.31M | -225.23M | -54.23M | -109.16M | -31.87M | -24.97M | -67.9M |
Debt / Equity | - | - | - | 0.03x | 0.04x | 0.06x | 0.06x | 0.08x | 0.07x |
Debt / EBITDA | - | - | - | - | - | - | - | - | -0.15x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | 1.27x |
Interest Coverage | - | - | - | - | - | - | - | - | -560.22x |
Total Equity | -45.84M▲ 0% | -61.46M▼ 34.1% | -101.05M▼ 64.4% | 207.88M▲ 305.7% | 146.97M▼ 29.3% | 169.76M▲ 15.5% | 125.93M▼ 25.8% | 133.14M▲ 5.7% | 123.33M▲ 0% |
Equity Growth % | - | -34.08% | -64.4% | 305.72% | -29.3% | 15.51% | -25.82% | 5.72% | -4.68% |
Book Value per Share | -1.28 | -1.71 | -7.22 | 5.78 | 4.06 | 4.07 | 2.61 | 27.33 | 11.00 |
Total Shareholders' Equity | -45.84M | -61.46M | -101.05M | 207.88M | 146.97M | 169.76M | 125.93M | 133.14M | 123.33M |
Common Stock | 19K | 3K | 3K | 36K | 36K | 48K | 48K | 11K | 11K |
Retained Earnings | -50.27M | -67.08M | -111.34M | -145.45M | -214.22M | -282.38M | -331.62M | -230.05M | -240.67M |
Treasury Stock | -4.41M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | -763K | -48K | 68K | 87K | -17K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IMA Cash Flow Statement
ImageneBio Inc (IMA) cash flow — operating, investing & free cash flow history
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -11.61M | 47.93M | -37.83M | -60.25M | -74.11M | -79.74M | -46M | -47.84M | -52.08M |
Operating CF Margin % | -1172.53% | 348.48% | -411.42% | -194.46% | -474.51% | -870.56% | -1314.4% | -5980.5% | - |
Operating CF Growth % | - | 512.88% | -178.92% | -59.29% | -23% | -7.6% | 42.31% | -4% | -180.88% |
Net Income | -40.87M | -16.82M | -44.26M | -34.12M | -68.77M | -68.17M | -49.23M | -52.4M | -45.07M |
Depreciation & Amortization | 422K | 243K | 300K | 544K | 751K | 1.02M | 490K | 328K | 616K |
Stock-Based Compensation | 314K | 1.17M | 1.8M | 5.18M | 7.53M | 0 | 5.29M | 15.39M | 1.39M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 29.02M | -121K | 12.1M | 1.17M | 1.52M | 9.07M | 1.42M | 8.02M | 12.13M |
Working Capital Changes | 58K | 63.45M | -7.77M | -33.03M | -15.14M | -21.67M | -3.98M | -19.19M | -21.14M |
Change in Receivables | 0 | -1.33M | 519K | 361K | -291K | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 1.33M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 602K | -1.33M | 0 | 0 | 0 | -2.87M | -1.17M | -2.82M | -3.6M |
Cash from Investing | 10.97M | -316K | 2.92M | -1.76M | -99.28M | 64.14M | -34.9M | -5.81M | -14.19M |
Capital Expenditures | -305K | -316K | -766K | -1.76M | -1.43M | -414K | 0 | 0 | 0 |
CapEx % of Revenue | 30.81% | 2.3% | 8.33% | 5.68% | 9.16% | 4.52% | - | - | - |
Acquisitions | 11.27M | 0 | 3.69M | 0 | 0 | 0 | 0 | -5.21M | -5.21M |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | 11.27M | 0 | 0 | 0 | 0 | 0 | -7.07M | 0 | 0 |
Cash from Financing | 0 | 16.32M | 116.18M | 131.74M | 1.09M | 75.98M | 0 | 135.47M | 132.22M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15M | 15M |
Equity Issued (Net) | 0 | 16.29M | 116.11M | 131.16M | 0 | 36.89M | 0 | 65.84M | 62.59M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | -57K | 0 | 0 | -663K | 0 | 0 | 0 |
Other Financing | 0 | 25K | 70K | 582K | 1.09M | 39.09M | 0 | 54.63M | 54.63M |
Net Change in Cash | -639K▲ 0% | 63.93M▲ 10104.2% | 81.28M▲ 27.1% | 69.73M▼ 14.2% | -172.3M▼ 347.1% | 59.98M▲ 134.8% | -80.91M▼ 234.9% | 82.41M▲ 201.9% | 39.28M▲ 0% |
Free Cash Flow | -11.91M▲ 0% | 47.61M▲ 499.7% | -38.59M▼ 181.1% | -62.01M▼ 60.7% | -75.54M▼ 21.8% | -80.16M▼ 6.1% | -46M▲ 42.6% | -47.84M▼ 4.0% | -52.08M▲ 0% |
FCF Margin % | -1203.33% | 346.19% | -419.75% | -200.14% | -483.67% | -875.08% | -1314.4% | -5980.5% | - |
FCF Growth % | - | 499.66% | -181.06% | -60.69% | -21.82% | -6.11% | 42.61% | -4% | -36.12% |
FCF per Share | -0.33 | 1.33 | -2.76 | -1.72 | -2.09 | -1.92 | -0.95 | -9.82 | -4.65 |
FCF Conversion (FCF/Net Income) | 0.28x | -2.85x | 0.85x | 1.77x | 1.08x | 1.17x | 1.26x | 1.06x | 1.16x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IMA Key Ratios
ImageneBio Inc (IMA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -63.87% | -38.76% | -43.04% | -24.73% | -35.01% | -35.2% |
| Return on Invested Capital (ROIC) | - | - | - | -141.07% | -73.77% | -35.88% | -35.94% | -61.12% |
| Gross Margin | -81.33% | -387.79% | -52.03% | -311.84% | 88.86% | 100% | -29.13% | - |
| Net Margin | -122.28% | -481.36% | -110.1% | -440.29% | -744.17% | -1044.8% | -5668.63% | - |
| Debt / Equity | - | - | 0.03x | 0.04x | 0.06x | 0.06x | 0.08x | 0.07x |
| Interest Coverage | - | - | - | - | - | - | - | -560.22x |
| FCF Conversion | -2.85x | 0.85x | 1.77x | 1.08x | 1.17x | 1.26x | 1.06x | 1.16x |
| Revenue Growth | 1289.19% | -33.15% | 237.01% | -49.59% | -41.35% | -61.79% | -77.14% | - |
Related:IMA Dividend History·IMA Revenue History·IMA Price History·IMA P/E History·IMA Financial Ratios·IMA Institutional Holders
IMA SEC Filings & Documents
ImageneBio Inc (IMA) SEC filings — annual & quarterly reports (10-K, 10-Q)
IMA Frequently Asked Questions
ImageneBio Inc (IMA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
ImageneBio Inc (IMA) reported $0.8M in revenue for fiscal year 2025. This represents a 19% decrease from $1.0M in 2018.
ImageneBio Inc (IMA) saw revenue decline by 77.1% over the past year.
ImageneBio Inc (IMA) reported a net loss of $45.1M for fiscal year 2025.
Dividend & Returns
ImageneBio Inc (IMA) has a return on equity (ROE) of -35.0%. Negative ROE indicates the company is unprofitable.
ImageneBio Inc (IMA) had negative free cash flow of $52.1M in fiscal year 2025, likely due to heavy capital investments.